




PHARMACEUTICAL 2022

Anebulo Pharmaceuticals Inc.
Rank 303 of 466





PHARMACEUTICAL 2022

Anebulo Pharmaceuticals Inc.
Rank 303 of 466

The relative strengths and weaknesses of Anebulo Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Anebulo Pharmaceuticals Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 1,905% points. The greatest weakness of Anebulo Pharmaceuticals Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 242% points.

The company's Economic Capital Ratio, given in the ranking table, is 60%, being 18% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	0
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	110
Liabilities, Non-Current	0
Other Assets	21,653
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	132
Other Net Income	-26,639
Other Revenues	0
Property and Equipment	0
Research and Development	2,270
Selling, General and Administrative Expense	1,344

Output Variable	Value in 1000 USD
Assets	21,653
Liabilities	242
Expenses	3,614
Revenues	0
Stockholders Equity	21,412
Net Income	-30,253
Comprehensive Net Income	-30,253
Economic Capital Ratio	60%